TheraRadar

Talphera

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 9/28/2016

17
Total Trials
7
Phase 3
6
Phase 2
0
Recruiting
165
Score

Pipeline by Phase

Phase 3
7
Phase 2
6
Phase 1
4

Therapeutic Focus

Post-Operative Pain Moderate-to-severe Acute Pain Pharmacokinetics Post Operative Pain Pain

Clinical Trials (17)

NCT02662764 Phase 3 COMPLETED

Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

Started: 9/28/2016

NCT02447848 Phase 3 COMPLETED

Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

Started: 10/1/2015

NCT02662556 Phase 3 COMPLETED

A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

Started: 3/1/2016

NCT02356588 Phase 3 COMPLETED

A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery

Started: 2/1/2015

NCT01539642 Phase 3 COMPLETED

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

Started: 2/1/2012

NCT01660763 Phase 3 COMPLETED

Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

Started: 8/1/2012

NCT01539538 Phase 3 COMPLETED

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Started: 4/1/2012

NCT01710345 Phase 2 COMPLETED

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Started: 10/1/2012

NCT00718081 Phase 2 COMPLETED

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery

Started: 8/1/2008

NCT00833040 Phase 2 COMPLETED

A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain

Started: 4/1/2009

NCT00894699 Phase 2 COMPLETED

A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

Started: 6/1/2009

NCT00612534 Phase 2 COMPLETED

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement

Started: 3/1/2008

NCT00859313 Phase 2 COMPLETED

An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement

Started: 4/1/2009

NCT02082236 Phase 1 COMPLETED

Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

Started: 5/1/2014

NCT01721070 Phase 1 COMPLETED

Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

Started: 11/1/2012

NCT01761565 Phase 1 COMPLETED

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

Started: 1/1/2013

NCT01639729 Phase 1 COMPLETED

Effect of Delivery Route on PK of Sufentanil NanoTab

Started: 7/1/2012

Drug Candidates

Zalviso™ 15 mcg Treatment Arm A: Sufenta® Treatment B: Sufentanil SSM 30 mcg Treatment C: SSM 15 mcg Treatment D: SSM 30 mcg sufentanil sublingual 30 mcg tablet sufentanil sublingual tablet 30 mcg Sufentanil Tablet 30 mcg Placebo Tablet Sufentanil NanoTab (SUF NT) 15 mcg
Activity Status: Inactive
Last Trial Started: 9/28/2016
Last Trial Ended: 5/5/2017
Trials (12 months): 0
Completed Trials: 17
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.